Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853028 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1RXFP1TDP1LMNA | |
| SCHEMBL4854652 | 0.89 | LMNA (0.47) | KDM4EALDH1A1RXFP1TDP1LMNA | |
| SCHEMBL4853398 | 0.87 | KDM4E (0.43) | KDM4EALDH1A1RXFP1LMNAKMT2A | |
| SCHEMBL4854822 | 0.86 | KDM4E (0.47) | KDM4EALDH1A1 | |
| SCHEMBL4854733 | 0.86 | KDM4E (0.49) | KDM4EALDH1A1RXFP1LMNAKMT2A | |
| SCHEMBL14223430 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1RXFP1TDP1LMNA | |
| SCHEMBL4856185 | 0.82 | ALDH1A1 (0.45) | KDM4EALDH1A1LMNAKMT2AGAA | |
| SCHEMBL4854600 | 0.79 | ALDH1A1 (0.55) | KDM4EALDH1A1RXFP1TDP1LMNA | |
| SCHEMBL4855957 | 0.79 | KDM4E (0.47) | KDM4EALDH1A1RXFP1TDP1LMNA | |
| SCHEMBL4854626 | 0.79 | KDM4E (0.47) | KDM4EALDH1A1RXFP1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | claimed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | claimed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | KDM4E 4161/4885ALDH1A1 272/4885RXFP1 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.